vs
Side-by-side financial comparison of Alkermes plc. (ALKS) and SSR MINING INC. (SSRM). Click either name above to swap in a different company.
SSR MINING INC. is the larger business by last-quarter revenue ($521.7M vs $384.5M, roughly 1.4× Alkermes plc.). SSR MINING INC. runs the higher net margin — 34.8% vs 12.8%, a 21.9% gap on every dollar of revenue. On growth, SSR MINING INC. posted the faster year-over-year revenue change (61.4% vs -10.6%). Alkermes plc. produced more free cash flow last quarter ($170.0M vs $106.4M). Over the past eight quarters, SSR MINING INC.'s revenue compounded faster (50.5% CAGR vs 4.8%).
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.
SSR Mining Inc., formerly Silver Standard Resources is a Denver-based gold, silver, copper, lead and zinc producer that owns the largest silver mine in Argentina. In addition it engages in exploration activity throughout the Americas and Turkey. In 2020, SSR Mining merged with Alacer Gold. Since the merger, the company has moved headquarters to Denver, Colorado. Rodney P. Antal is now the president and CEO of SSR mining. In February 2021, SSR Mining announced that Alison White would be the ne...
ALKS vs SSRM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $384.5M | $521.7M |
| Net Profit | $49.3M | $181.5M |
| Gross Margin | 88.0% | — |
| Operating Margin | 15.1% | 38.8% |
| Net Margin | 12.8% | 34.8% |
| Revenue YoY | -10.6% | 61.4% |
| Net Profit YoY | -66.3% | 3166.6% |
| EPS (diluted) | $0.29 | $0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $384.5M | $521.7M | ||
| Q3 25 | $394.2M | $385.8M | ||
| Q2 25 | $390.7M | $405.5M | ||
| Q1 25 | $306.5M | $316.6M | ||
| Q4 24 | $430.0M | $323.2M | ||
| Q3 24 | $378.1M | $257.4M | ||
| Q2 24 | $399.1M | $184.8M | ||
| Q1 24 | $350.4M | $230.2M |
| Q4 25 | $49.3M | $181.5M | ||
| Q3 25 | $82.8M | $65.4M | ||
| Q2 25 | $87.1M | $90.1M | ||
| Q1 25 | $22.5M | $58.8M | ||
| Q4 24 | $146.5M | $5.6M | ||
| Q3 24 | $92.4M | $10.6M | ||
| Q2 24 | $91.4M | $9.7M | ||
| Q1 24 | $36.8M | $-287.1M |
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | — | ||
| Q2 25 | 87.3% | — | ||
| Q1 25 | 83.9% | — | ||
| Q4 24 | 85.6% | — | ||
| Q3 24 | 83.3% | — | ||
| Q2 24 | 84.6% | — | ||
| Q1 24 | 83.3% | — |
| Q4 25 | 15.1% | 38.8% | ||
| Q3 25 | 22.6% | 21.6% | ||
| Q2 25 | 23.8% | 26.9% | ||
| Q1 25 | 4.5% | 21.1% | ||
| Q4 24 | 37.8% | 10.6% | ||
| Q3 24 | 27.7% | 3.5% | ||
| Q2 24 | 27.5% | 5.8% | ||
| Q1 24 | 12.4% | -163.5% |
| Q4 25 | 12.8% | 34.8% | ||
| Q3 25 | 21.0% | 17.0% | ||
| Q2 25 | 22.3% | 22.2% | ||
| Q1 25 | 7.3% | 18.6% | ||
| Q4 24 | 34.1% | 1.7% | ||
| Q3 24 | 24.4% | 4.1% | ||
| Q2 24 | 22.9% | 5.2% | ||
| Q1 24 | 10.5% | -124.7% |
| Q4 25 | $0.29 | $0.84 | ||
| Q3 25 | $0.49 | $0.31 | ||
| Q2 25 | $0.52 | $0.42 | ||
| Q1 25 | $0.13 | $0.28 | ||
| Q4 24 | $0.88 | $0.03 | ||
| Q3 24 | $0.55 | $0.05 | ||
| Q2 24 | $0.53 | $0.05 | ||
| Q1 24 | $0.21 | $-1.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.6M | $575.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $3.5B |
| Total Assets | $2.5B | $6.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.6M | $575.6M | ||
| Q3 25 | $616.4M | $445.4M | ||
| Q2 25 | $521.2M | $438.5M | ||
| Q1 25 | $399.8M | $341.3M | ||
| Q4 24 | $291.1M | $417.3M | ||
| Q3 24 | $396.3M | $365.8M | ||
| Q2 24 | $535.1M | $384.4M | ||
| Q1 24 | $420.8M | $492.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $228.6M | ||
| Q3 24 | — | $228.3M | ||
| Q2 24 | — | $228.0M | ||
| Q1 24 | — | $228.7M |
| Q4 25 | $1.8B | $3.5B | ||
| Q3 25 | $1.7B | $3.3B | ||
| Q2 25 | $1.6B | $3.3B | ||
| Q1 25 | $1.5B | $3.2B | ||
| Q4 24 | $1.5B | $3.1B | ||
| Q3 24 | $1.3B | $3.1B | ||
| Q2 24 | $1.3B | $3.1B | ||
| Q1 24 | $1.3B | $3.1B |
| Q4 25 | $2.5B | $6.1B | ||
| Q3 25 | $2.3B | $5.9B | ||
| Q2 25 | $2.3B | $5.8B | ||
| Q1 25 | $2.1B | $5.6B | ||
| Q4 24 | $2.1B | $5.2B | ||
| Q3 24 | $2.2B | $5.1B | ||
| Q2 24 | $2.2B | $5.2B | ||
| Q1 24 | $2.1B | $5.3B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.07× | ||
| Q3 24 | — | 0.07× | ||
| Q2 24 | — | 0.07× | ||
| Q1 24 | — | 0.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $170.1M | $172.1M |
| Free Cash FlowOCF − Capex | $170.0M | $106.4M |
| FCF MarginFCF / Revenue | 44.2% | 20.4% |
| Capex IntensityCapex / Revenue | 0.0% | 12.6% |
| Cash ConversionOCF / Net Profit | 3.45× | 0.95× |
| TTM Free Cash FlowTrailing 4 quarters | $480.3M | $241.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $170.1M | $172.1M | ||
| Q3 25 | $101.7M | $57.2M | ||
| Q2 25 | $150.2M | $157.8M | ||
| Q1 25 | $98.8M | $84.8M | ||
| Q4 24 | $190.4M | $95.0M | ||
| Q3 24 | $81.6M | $-1.3M | ||
| Q2 24 | $146.0M | $-78.1M | ||
| Q1 24 | $21.1M | $24.6M |
| Q4 25 | $170.0M | $106.4M | ||
| Q3 25 | $84.4M | $-2.4M | ||
| Q2 25 | $137.2M | $98.4M | ||
| Q1 25 | $88.7M | $39.3M | ||
| Q4 24 | $180.6M | $56.4M | ||
| Q3 24 | $73.3M | $-34.1M | ||
| Q2 24 | $138.9M | $-116.3M | ||
| Q1 24 | $12.8M | $-9.4M |
| Q4 25 | 44.2% | 20.4% | ||
| Q3 25 | 21.4% | -0.6% | ||
| Q2 25 | 35.1% | 24.3% | ||
| Q1 25 | 28.9% | 12.4% | ||
| Q4 24 | 42.0% | 17.5% | ||
| Q3 24 | 19.4% | -13.2% | ||
| Q2 24 | 34.8% | -62.9% | ||
| Q1 24 | 3.6% | -4.1% |
| Q4 25 | 0.0% | 12.6% | ||
| Q3 25 | 4.4% | 15.4% | ||
| Q2 25 | 3.3% | 14.7% | ||
| Q1 25 | 3.3% | 14.4% | ||
| Q4 24 | 2.3% | 11.9% | ||
| Q3 24 | 2.2% | 12.7% | ||
| Q2 24 | 1.8% | 20.7% | ||
| Q1 24 | 2.4% | 14.8% |
| Q4 25 | 3.45× | 0.95× | ||
| Q3 25 | 1.23× | 0.87× | ||
| Q2 25 | 1.72× | 1.75× | ||
| Q1 25 | 4.40× | 1.44× | ||
| Q4 24 | 1.30× | 17.10× | ||
| Q3 24 | 0.88× | -0.13× | ||
| Q2 24 | 1.60× | -8.06× | ||
| Q1 24 | 0.57× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
SSRM
| Gold | $369.3M | 71% |
| Concentrate Sales | $124.4M | 24% |
| Other | $19.1M | 4% |
| Lead | $9.0M | 2% |
